Kraig Biocraft Laboratories, Inc., a global leader in spider silk technology, has secured usage rights to a strategic block of government-owned mulberry gardens located near its spider silk production operations in Southeast Asia, supporting a major expansion of its manufacturing capacity. The
Kraig Biocraft Laboratories, Inc. has confirmed that its spider silk production operations in Vietnam remain fully secure and uninterrupted, despite recent typhoons that caused widespread flooding in parts of Southeast Asia. The company attributed the operational continuity to its strategic relocation of production facilities to highland regions over the past two years.
Kraig Biocraft Laboratories Inc., a leading developer of recombinant spider silk-based fibers, announced the signing of a significant production agreement aimed at scaling up its proprietary spider silk technology. This milestone builds upon the successful rollout earlier this year of Kraig Labs’ innovative spider silk production hybrids. Under the terms of the
Kraig Biocraft Laboratories, Inc. announces record-setting progress in the production of its BAM-1 spider silk hybrid strain, noting unprecedented growth in silkworm size, growth, and robustness. In early June, the company accelerated its production schedule for the new BAM-1 hybrids following successful spring production trials. The first batch of these production hybrids
Kraig Biocraft Laboratories, Inc., the biotechnology company focused on the development and commercialization of spider silk, recently announced the early start to the production season with the successful manufacture and delivery of the most recent batch of recombinant spider silk. Silk from this production cycle was processed into finished reeled raw silk and received
















